Maxim Group Initiates Coverage On Lexaria Bioscience with Buy Rating, Announces Price Target of $2
Portfolio Pulse from richadhand@benzinga.com
Maxim Group analyst Michael Okunewitch has initiated coverage on Lexaria Bioscience (NASDAQ:LEXX) with a Buy rating and a price target of $2.
July 21, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience has been initiated with a Buy rating and a price target of $2 by Maxim Group.
The initiation of coverage by Maxim Group with a Buy rating and a price target of $2 indicates a positive outlook for Lexaria Bioscience. This could potentially lead to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100